Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3008 A Single-Center Retrospective Analysis of Thymic Neuroendocrine Tumor

Introduction: Thymic neuroendocrine tumor (NET) is a rare type of tumor located in the anterior mediastinum.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Chen J,

Keywords: thymic neuroendocrine tumor, atypical carcinoid,

#2191 Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms

Introduction: Endocrine paraneoplastic syndromes (ePNS) result from production of bioactive substances from tumours not related to their expected tissue of origin. Neuroendocrine neoplasms (NENs) have been associated with ectopic secretion of several hormones, but the prevalence of ePNS has only been described in a small number of studies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chatzellis E, Alexandraki K, Angelousi A, Tsoli M, Kaltsatou M,

Keywords: paraneoplastic syndromes, neuroendocrine neoplasms, ectopic secretion,

#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,

#1918 Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour

Introduction: Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kavan P

Authors: Stavrides-Eid M, Soo Rho Y, Barrera I, Kavan P,

Keywords: thymic neuroendocrine tumour, pembrolizumab, atypical carcinoid, NETs,

#1862 Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms

Introduction: Metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs) is associated with a more aggressive behaviour

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alexandraki K, Boutzios G, Nikolopoulos G, Tsoli M, Thomas D,

Keywords: bone disease,